Table 1 Antifungal activity of mandimycin against WHO priority fungal pathogens
From: A polyene macrolide targeting phospholipids in the fungal cell membrane
WHO priority group | MDR pathogen | Resistant phenotype | MIC (μg ml−1) |
---|---|---|---|
Critical priority | Candida auris BNCC 357785 | FCAR, 5-FUR, TBFR | 1 |
Candida auris BNCC 357784 | FCAR, 5-FUR, TBFR | 1 | |
Candida auris AMR05 | AmpR, FCAR, 5-FUR, TBFR | 2 | |
Candida albicans BNCC 186382 | FCAR | 0.25 | |
Candida albicans BNCC 337321 | FCAR, 5-FUR, TBFR | 0.5 | |
Candida albicans BNCC 336485 | FCAR, 5-FUR, TBFR | 0.5 | |
Cryptococcus neoformans BNCC 225501 | CPFR, FCAR, 5-FUR | 0.125 | |
Cryptococcus neoformans BNCC 356067 | CPFR, FCAR, 5-FUR | 0.125 | |
Aspergillus fumigatus BNCC 122691 | FCAR, 5-FUR, TBFR | 2 | |
Aspergillus fumigatus BNCC 340016 | FCAR, 5-FUR, TBFR | 2 | |
High priority | Candida glabrata BNCC 337348 | CPFR, FCAR, 5-FUR, TBFR | 0.25 |
Candida tropicalis BNCC 340288 | 5-FUR | 0.5 | |
Candida parapsilosis BNCC 337317 | TBFR, 5-FUR | 1 | |
Mucor sp. BNCC 195604 | FCAR, 5-FUR | 0.25 | |
Fusarium sp. BNCC 340967 | CPFR, FCAR, 5-FUR | 1 | |
Exophiala dermatitidis BNCC 360135 | CPFR, FCAR, 5-FUR | 1 | |
Medium priority | Candida krusei BNCC 185429 | CPFR, FCAR, 5-FUR, TBFR | 2 |
Cryptococcus gattii BNCC 354891 | FCAR, 5-FUR,TBFR | 0.25 | |
Talaromyces marneffei BNCC 334957 | CPFR, FCAR, 5-FUR | 2 | |
Emergomyces pasteurianus BNCC 362479 | 5-FUR | 2 |